Nanosonics Limited: Strong Defensive Position and Growth Potential with Trophon and CORIS
Nanosonics Limited is positioned strongly with its Trophon franchise, enhancing margins and supporting the upcoming CORIS product aimed at infection control. Despite market underestimation, CORIS's advanced cleaning capabilities and the need for investment in clinical efficacy are noted. The Trophon franchise has diversified revenue streams, stabilizing earnings amid competition. Growth is seen in EMEA, Japan, and China through third-party distribution. Recent FDA approval of CORIS highlights its efficacy, but market access requires integration into clinical guidelines. Analyst Davinthra Thillainathan maintains a positive outlook with a Buy rating and A$4.50 price target.
Tip Ranks·